The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 470-479

  Ferreri, Andrés J M ^a,b   Govi, Silvia ^a,b   Ponzoni, Maurilio ^a,c  

^a Unit of Lymphoid Malignancies   (Italy)

^b Department of Onco Hematology   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Diffuse large B cell lymphoma; Eradicating therapy; Helicobacter pylori; Mucosa associated lymphoid tissue lymphoma; Primary gastric lymphoma

Indexed keywords

AMOXICILLIN; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; METRONIDAZOLE; OXALIPLATIN; PREDNISONE; PROTON PUMP INHIBITOR; RITUXIMAB; VINCRISTINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSERVATIVE TREATMENT; DISEASE CONTROL; DISEASE FREE SURVIVAL; ENDOSCOPIC BIOPSY; ENDOSCOPY; ERADICATION THERAPY; FOLLOW UP; GASTRECTOMY; GASTROSCOPY; HELICOBACTER INFECTION; HUMAN; LARGE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; REVIEW; SALVAGE THERAPY; STOMACH LYMPHOMA; TREATMENT RESPONSE; UREA BREATH TEST; COMPLICATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROBIOLOGY; STOMACH NEOPLASMS;

ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; STOMACH NEOPLASMS;

EID: 84883206171     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/01.cco.0000432523.24358.15     Document Type: Review

References (58)

1. Doglioni C, Wotherspoon AC, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339: 834-835.
2. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176.
3. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998; 338: 804-810.
4. Delchier JC, Lamarque D, Levy M, et al. Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type. Am J Gastroenterol 2001; 96: 2324-2328.
5. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 2005; 128: 1579-1605.
6. Ferreri AJ, Cordio S, Ponzoni M, Villa E. Nonsurgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma. Leuk Lymphoma 1999; 33: 531-541.
7. Ferreri AJ, Freschi M, Dell'Oro S, et al. Prognostic significance of the histopathologic recognition of low-and high-grade components in stage III B-cell gastric lymphomas. Am J Surg Pathol 2001; 25: 95-102.
8. Ng WW, Lam CP, Chau WK, et al. Regression of high-grade gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter pylori after triple antibiotic therapy. Gastrointest Endosc 2000; 51: 93-96.
9. Alsolaiman MM, Bakis G, Nazeer T, et al. Five years of complete remission of gastric diffuse large B cell lymphoma after eradication of Helicobacter pylori infection. Gut 2003; 52: 507-509.
10. Miyamoto S, Okamoto R, Maeda Y, et al. Two cases of stomach primary diffuse large B cell lymphoma remitted by Helicobacter pylori eradication therapy. Gan To Kagaku Ryoho 2008; 35: 2437-2440.
11. Ruskone-Fourmestraux A. MALT gastric lymphomas. Rev Med Interne 2004; 25: 573-581.
12. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877.
13. Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 2007; 63: 65-71.
14. Levy M, Copie-Bergman C, Traulle C, et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 2002; 97: 292-297.
15. Wotherspoon AC, Pan LX, Diss TC, Isaacson PG. Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet 1992; 58: 35-38.
16. Andriani A, Zullo A, Di Raimondo F, et al. Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Aliment Pharmacol Ther 2006; 23: 721-726.
17. Graham DY, Qureshi WA. Antibiotic-resistant H. pylori infection and its treatment. Curr Pharm Des 2000; 6: 1537-1544.
18. Lehours P, Ruskone-Fourmestraux A, Lavergne A, et al., Groupe d'Etude des Lymphomes Digestifs (GELD) for the Federation Francaise de Cancerologie Digestive (FFCD). Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003; 98: 291-295.
19. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.
20. Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas (author's transl). Strahlentherapie 1977; 153: 218-221.
21. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400.
22. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007; 56: 1685-1687.
23. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781.
24. Zullo A, Severi C, Vannella L, et al. Role of gastritis pattern on Helicobacter pylori eradication. Intern Emerg Med 2012; 7: 517-522.
25. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758.
26. Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009; 144: 367-375.
27. Copie-Bergman C, Wotherspoon AC, Capella C, et al. Gela histological scoring system for posttreatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 2013; 160: 47-52. This article regards the histopathological score to define response and progressive disease in gastric marginal zone lymphoma.
28. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294.
29. Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematop 2007; 47: 31-42.
30. Nakamura S, Ye H, Bacon CM, et al. Gastric MALT lymphoma with t(14;18)(q32;q21) involving IGH and BCL2 genes that responded to Helicobacter pylori eradication. J Clin Pathol 2007; 60: 1171-1173.
31. Alpen B, Robbecke J, Wundisch T, et al. Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL). Ann Hematol 2001; 80 (Suppl 3):B106-B107.
32. Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003; 63: 737-741.
33. Iwano M, Okazaki K, Uchida K, et al. Characteristics of gastric B-cell lymphoma of mucosa-associated lymphoid tissue type involving multiple organs. J Gastroenterol 2004; 39: 739-746.
34. Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of lowgrade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106: 1037-1041.
35. Raderer M, Streubel B, Wohrer S, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616-618.
36. Copie-Bergman C, Wotherspoon A. MALT lymphoma pathology, initial diagnosis, and posttreatment evaluation. 1st ed London, UK: Healthcare I; 2008.
37. Copie-Bergman C, Locher C, Levy M, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol 2005; 16: 1232-1236.
38. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007; 136: 521-538.
39. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosaassociated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005; 23: 5061-5066.
40. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
41. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG- 19 Randomized Study. J Clin Oncol 2013; 31: 565-572. This is the unique randomized trial addressing safety and activity of chlorambucil-rituximab combination in extranodal marginal zone lymphoma.
42. Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004; 66: 476-480.
43. Montalban C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 1995; 6: 355-362.
44. Haim N, Leviov M, Ben-Arieh Y, et al. Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of nonsurgical treatment with primary chemotherapy, with or without radiotherapy. Leuk Lymphoma 1995; 17: 321-326.
45. Aviles A, Nambo MJ, Neri N, et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 2004; 240: 44-50.
46. Binn M, Ruskone-Fourmestraux A, Lepage E, et al. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 2003; 14: 1751-1757.
47. Martinelli G, Gigli F, Calabrese L, et al. Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]. Leuk Lymphoma 2009; 50: 925-931.
48. Tondini C, Balzarotti M, Santoro A, et al. Initial chemotherapy for primary resectable large-cell lymphoma of the stomach [see comments]. Ann Oncol 1997; 8: 497-499.
49. Raderer M, Chott A, Drach J, et al. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol 2002; 13: 1094-1098.
50. Tari A, Asaoku H, Kashiwado K, et al. Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endosc 2009; 21: 219-227.
51. Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001; 19: 2041-2048.
52. Cavanna L, Pagani R, Seghini P, et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. World J Surg Oncol 2008; 6: 35.
53. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001; 19: 4245-4251.
54. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001; 19: 4245-4251. 19(22): 4245-4251.
55. Ferreri AJ, Govi S, Raderer M, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood 2012; 120: 3858-3860. This is the first prospective phase II trial addressing activity and efficacy of H. pylori eradication with antibiotics as exclusive treatment in western patients with limitedstage gastric DLBCL.
56. Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012; 119: 4838-4844. The largest retrospective series of patients with limited-stage gastric DLBCL managed with H. pylori eradication with antibiotics as exclusive treatment.
57. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
58. Kuo SH, Chen LT, Wu MS, et al. Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment. Ann Surg 2008; 247: 265-269.